1Thompson DD, Simmons HA, Pifie CM, et al. FDA guidelines and animal models for osteoporosis[J]. Bone, 1995 ,17(4 Suppl) : 125S-133S.
2Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro[J]. Bone,2002,30(2) :368-376.
3Quinn JM, Itoh K, Udagawa N, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions[J]. J Bone Miner Res, 2001 , 16(10) : 1787-1794.
4Lee K, Jessop H, SuswiUo R, et al. Endocrinology: bone adaptation requires oestrogen receptor-alpha[ J]. Nature, 2003, 424(6947) :389.
5Kian TM, Rogatsky I, Tzagarakis-Foster C, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta[J]. Mol Biol Cell,2004 ,15(3) :1262-1272.
4Hansdottir H,Franzson L,Prestwood K,et al.The effect of ratoxifene on markers of bone turnover in older women living in long-term care facilities [J].J Am Geriatr Soc,2004,52(5):779-785.
